| Year |
Citation |
Score |
| 2019 |
Stover EH, Baco MB, Cohen O, Li Y, Christie E, Bagul M, Goodale A, Lee Y, Pantel S, Rees M, Wei G, Presser A, Zervantonakis I, Bhola P, Ryan J, et al. Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Ap14 |
0.315 |
|
| 2019 |
Rosenbluth J, Zervantonakis I, Boedicker M, Wagle N, Dillon D, Nakhlis F, Brugge J, Overmoyer B. Abstract P5-17-01: Patient-derived organoid models of inflammatory breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P5-17-01 |
0.354 |
|
| 2018 |
Hamalian S, Güth R, Zervantonakis I, Duell E, Lin J, Shisgal P, Molnar J, Geller C, Agajanian M, Tchou J, Sorger PK, Brugge JS, Kelber JA. Abstract 2140: Mesenchymal stromal cells expressing a PEAK1/Cripto axis sustain pro-survival NF-κB signaling in adjacent tumor cells to promote disease progression and therapy resistance Cancer Research. 78: 2140-2140. DOI: 10.1158/1538-7445.Am2018-2140 |
0.41 |
|
| 2017 |
Iavarone C, Zervantonakis I, Selfors LM, Palakurthi S, Liu JF, Matulonis UA, Drapkin RI, Mills GB, Leverson JD, Sampath D, Brugge JS. Abstract 4033: Combined MEK and BCL-2/XLinhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer Cancer Research. 77: 4033-4033. DOI: 10.1158/1538-7445.Am2017-4033 |
0.42 |
|
| 2016 |
Iwanicki MP, Chen H, Zervantonakis I, Novak M, Muranen T, Ince TA, Drapkin R, Brugge JS. Abstract PR12: Mutant p53 drives early events in fallopian tube tumorigenesis through mesenchyme-associated autocrine production of matrix that supports survival and mesothelial intercalation. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-Pr12 |
0.375 |
|
| 2016 |
Iavarone C, Zervantonakis I, Chen H, Palakurthi SS, Liu JF, Matulonis UA, Drapkin RI, Mills GB, Leverson JD, Sampath D, Brugge JS. Abstract B48: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B48 |
0.424 |
|
| 2016 |
Iavarone C, Zervantonakis I, Chen H, Palakurthi SS, Liu JF, Matulonis U, Drapkin R, Mills G, Leverson J, Sampath D, Brugge J. Abstract 3843: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models Cancer Research. 76: 3843-3843. DOI: 10.1158/1538-7445.Am2016-3843 |
0.422 |
|
| 2015 |
Zervantonakis I, Chen H, Muranen T, Liu J, Drapkin R, Matulonis U, Brugge J. Abstract PR01: Adaptive resistance of patient-derived ovarian cancer cells to PI3K/mTOR inhibition Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr01 |
0.424 |
|
| 2011 |
Luo Y, Zervantonakis I, Oh SB, Kamm RD, Barbastathis G. Spectrum resolved fluorescence imaging in multi-focal volume holographic microscopy Proceedings of Spie. 7891. DOI: 10.1117/12.874570 |
0.386 |
|
| 2010 |
Chung S, Sudo R, Vickerman V, Zervantonakis IK, Kamm RD. Microfluidic platforms for studies of angiogenesis, cell migration, and cell-cell interactions. Sixth International Bio-Fluid Mechanics Symposium and Workshop March 28-30, 2008 Pasadena, California. Annals of Biomedical Engineering. 38: 1164-77. PMID 20336839 DOI: 10.1007/S10439-010-9899-3 |
0.485 |
|
| 2010 |
Zervantonakis I, Chung S, Sudo R, Zhang M, Charest J, Kamm R. Concentration gradients in microfluidic 3D matrix cell culture systems International Journal of Micro-Nano Scale Transport. 1: 27-36. DOI: 10.1260/1759-3093.1.1.27 |
0.488 |
|
| 2008 |
Das SK, Chung S, Zervantonakis I, Atnafu J, Kamm RD. A microfluidic platform for studying the effects of small temperature gradients in an incubator environment. Biomicrofluidics. 2: 34106. PMID 19693373 DOI: 10.1063/1.2988313 |
0.439 |
|
| Show low-probability matches. |